Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Copanlisib, sold under the brand name Aliqopa, is a medication used for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies.
The analysis highlights History, Community and Culture as prominent areas in the source structure around Copanlisib.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Explore different angles and find fresh ideas to shape your next piece of content.
Search suggestions related to this topic. Open a question to research it further; suggestions are not verified answers.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
You can skip this section if you’re here for content ideas and keyword inspiration.
The extracted context around Copanlisib shows recurring relationship patterns in the source. For example, Copanlisib → B-cell, Consequently, HER2, HER2-inhibitors, HER2-positive, Hodgkin, III, NHL, Phase II, R-B, R-CHOP, Two Another extracted example is Copanlisib → Drug Administration, FDA, February, Food, In September, May, The New. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
lymphoma follicular drug treatment clinical trials status phase adults relapsed two fda effects data name aliqopa us legal trial cancer
TTTA extracted 53 structured relationships around Copanlisib. Examples in this analysis include Copanlisib → 3D model (JSmol) → Interactive image and Copanlisib → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Copanlisib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Copanlisib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Copanlisib | ATC code | L01EM02 (WHO) | 1.00 | infobox |
| Copanlisib | CAS Number | 1032568-63-0 | 1.00 | infobox |
| Copanlisib | ChEBI | CHEBI:173077 | 1.00 | infobox |
| Copanlisib | ChEMBL | ChEMBL3218576 | 1.00 | infobox |
| Copanlisib | ChemSpider | 25069683 | 1.00 | infobox |
| Copanlisib | CompTox Dashboard (EPA) | DTXSID00145728 | 1.00 | infobox |
| Copanlisib | Drug class | PI3-Kinase inhibitor | 1.00 | infobox |
| Copanlisib | DrugBank | DB12483 | 1.00 | infobox |
| Copanlisib | Elimination half-life | 39.1 hours (range: 14.6 to 82.4) | 1.00 | infobox |
| Copanlisib | Excretion | Feces (64%), Urine (22%); 14% were not recovered | 1.00 | infobox |
| Copanlisib | Formula | C23H28N8O4 | 1.00 | infobox |
| Copanlisib | KEGG | D10867 | 1.00 | infobox |
| Copanlisib | Legal status | US: ℞-only | 1.00 | infobox |
| Copanlisib | License data | US DailyMed: Copanlisib | 1.00 | infobox |
| Copanlisib | License data | US FDA: 209936 | 1.00 | infobox |
| Copanlisib | MedlinePlus | a617044 | 1.00 | infobox |
| Copanlisib | Metabolism | CYP3A4/5 (≈90%), CYP1A1 (≈10%) | 1.00 | infobox |
| Copanlisib | Molar mass | 480.529 g·mol−1 | 1.00 | infobox |
| Copanlisib | Other names | BAY 80-6946 | 1.00 | infobox |
| Copanlisib | Protein binding | 84.2% | 1.00 | infobox |
| Copanlisib | PubChem CID | 24989044 | 1.00 | infobox |
| Copanlisib | Routes of administration | Intravenous | 1.00 | infobox |
| Copanlisib | Trade names | Aliqopa | 1.00 | infobox |
| Copanlisib | UNII | WI6V529FZ9 | 1.00 | infobox |
The concept neighborhoods around Copanlisib bring nearby vocabulary together. In this analysis, examples include Lymphoma, Drug and Effects. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Copanlisib, one of the stronger structural bridges in this analysis connects Copanlisib with Adverse effects. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Copanlisib to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Community & Culture, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Copanlisib · EN edition · Analysis: TopicsToTalkAbout
